Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

MRD2STOP (NCT04108624) is a prospective study looking at outcomes among patients with sustained multimodal MRD negativity who discontinue maintenance therapy. Primary endpoints were MRD resurgence rate at the 10-6 threshold, along with progression-free survival (and overall survival among those MRD negative by the standard non-enriched clonoSEQ. It was found that the discontinuation of maintenance therapy among these patients results in a high rate of sustained MRD-negativity and lack of disease progression and that CD138+-enriched MRD samples using the clonoSEQ assay may help to even better identify patients who can discontinue therapy.